Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study

AIDS. 2000 Jul 28;14(11):1655-6. doi: 10.1097/00002030-200007280-00022.
No abstract available

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / metabolism
  • HIV Infections / virology
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Male
  • Nevirapine / adverse effects
  • Nevirapine / therapeutic use*
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors / adverse effects
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Risk Factors
  • Viral Load*

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • Nevirapine